Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | CAR-T cell therapy DLBCL landscape

Ulrich Jäger • 12 Jun 2020
EHA 2020
Diffuse Large B-Cell Lymphoma Lymphoma Antibodies AUTO3 CAR-T Ibrutinib Pembrolizumab

Ulrich Jäger, MD, of the Medical University of Vienna, Vienna, Austria, discusses the current state of the art and future directions of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL) and novel data presented at EHA 2020. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ulrich Jäger

2:33
The effect of lymphodepleting agents on rate and severity of toxicities following CAR-T infusion
Ulrich Jäger • 16 Feb 2024
1:20
The importance of lymphodepletion, an undervalued component of the CAR-T therapy cycle
Ulrich Jäger • 16 Feb 2024
3:31
The role of lymphodepletion in CAR T-cell therapy: current knowledge & the need for personalization
Ulrich Jäger • 16 Feb 2024
0:58
CAR-T therapy in non-Hodgkin lymphoma: current status and future outlooks
Ulrich Jäger • 10 Feb 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals